News
Be the first to hear what’s happening with the GTI! Join our quarterly newsletter to receive direct updates, special announcements, upcoming events, and exclusive news.
Be the first to hear what’s happening with the GTI! Join our quarterly newsletter to receive direct updates, special announcements, upcoming events, and exclusive news.
Funding supports safety studies, manufacturing and clinical planning needed before applying to test the treatment in patients.
Two projects explore the rare Pitt-Hopkins and Rett syndromes using organoids that mimic organs.
UC San Diego is a world leader in gene therapy research — one child’s wish helped them get there.
The GTI is built on the belief that collaboration drives impact. A recent feature from UC San Diego Today highlights this mission in action, sharing how a GTI-facilitated connection brought together biotech entrepreneur Gavenraj Singh Sodhi and GTI co-director Dr. Alysson Muotri. Their shared interests have evolved into an exploration of brain organoid technology as a potential pathway for identifying treatments for rare diseases, including those affecting Sodhi’s daughter, Maddie.
The inaugural symposium brought together experts, funders, and patient advocates to highlight cutting-edge gene therapy advances and the power of collaboration.
Betty Cabrera, GTI Director of Research Engagement, participated as a panelist at the RARE Drug Development Symposium in Philadelphia, where discussions centered on innovative commercial and non-profit funding models for preclinical drug development. During the session, GTI showcased how UC San Diego researchers are leveraging rare disease research to drive advances in more prevalent disease.